Immuno-oncology latecomer GSK shows off PD-1 drug dataGlaxoSmithKline has new data showing that its cancer immunotherapy dostarlimab works as a second-line treatment for women with Share XImmuno-oncology latecomer GSK shows off PD-1 drug datahttps://pharmaphorum.com/news/immuno-oncology-latecomer-gsk-shows-off-pd-1-drug-data/
